Core Viewpoint - The animal health sector experienced a slight increase of 0.54% on January 22, with Xianfeng Holdings leading the gains. The Shanghai Composite Index rose by 0.14% to close at 4122.58, while the Shenzhen Component Index increased by 0.5% to 14327.05 [1]. Group 1: Stock Performance - Xianfeng Holdings (002141) closed at 4.19, up 9.97% with a trading volume of 720,300 shares and a transaction value of 297 million yuan [1]. - Other notable performers include Biological Shares (600201) at 17.60, up 1.79%, and Zhongmu Shares (600195) at 8.54, also up 1.79% [1]. - The overall trading volume and transaction values for various stocks in the animal health sector indicate active market participation [1]. Group 2: Capital Flow - The animal health sector saw a net inflow of 73.79 million yuan from institutional investors, while retail investors experienced a net outflow of 27.83 million yuan [2]. - The main capital inflow was primarily directed towards Xianfeng Holdings, which attracted 121 million yuan from institutional investors, representing 40.71% of its trading volume [3]. - Other stocks like Jinhe Biological (002688) and *ST Green Health (002868) also saw varying degrees of net inflow and outflow from different investor categories [3].

（文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：公司年报预告什么时候公示？ 瑞普生物（300119.SZ）1月22日在投资者互动平台表示，公司2025年度报告已预约2026年3月31日披 露，相关信息请以公司后续在深交所官网、巨潮资讯网发布的正式公告为准。 ...

（文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：现在家庭对宠物陪伴特别看重，贵公司是否会推出一 些宠物保健品或者营养品，提升宠物的体质健康和营养均衡。 瑞普生物（300119.SZ）1月22日在投资者互动平台表示，公司已推出氨糖软骨素、角鲨烯辅酶 Q10等多 款宠物营养保健品，26年即将上市磷虾鱼油、益生菌等产品，可助力宠物体质提升与营养均衡，契合养 宠家庭的宠物健康养护需求。未来公司将持续深耕该领域，丰富产品矩阵，为宠物提供更多优质的健康 解决方案。 ...

Core Viewpoint - The animal health sector experienced a decline of 0.65% on January 21, with Huisheng Biological leading the drop. The Shanghai Composite Index rose by 0.08%, while the Shenzhen Component Index increased by 0.7 [1] Group 1: Stock Performance - The closing prices and performance of key stocks in the animal health sector showed varied results, with Shunlian Biological up by 4.20% and Huisheng Biological down by 6.19% [1][2] - The trading volume for Huisheng Biological was 419,900 shares, with a transaction value of 1.192 billion yuan, indicating significant market activity despite the decline [2] Group 2: Capital Flow - The animal health sector saw a net inflow of 9.6935 million yuan from institutional investors, while retail investors experienced a net outflow of 73.8174 million yuan, suggesting a shift in investor sentiment [2][3] - Among individual stocks, Xianfeng Holdings had a net inflow of 15.1182 million yuan from institutional investors, while Huisheng Biological saw a net outflow of 42.2249 million yuan from retail investors [3]

Core Insights - The pet economy in China is rapidly expanding, with the market expected to exceed 811.4 billion yuan by 2025, and the urban pet population reaching 120 million [2][6]. Group 1: Industry Overview - The pet economy has evolved from mere companionship to a lifestyle, creating a vast ecosystem around the entire lifecycle of pets [5][6]. - The geographical distribution and specialization within the pet industry have developed into a national framework, with significant contributions from various regions [6][7]. Group 2: Regional Highlights - Liaoning Anshan is emerging as a major hub for pet breeding, supplying over 60% of the national pet dog and cat population, with an industry scale exceeding 10 billion yuan [18][19][20]. - Hebei and Shandong are recognized as the primary pet food production areas, with a projected 14% increase in pet food shipment volume by 2025 [30][31]. - The Yangtze River Delta is positioned as the "universe center" for pet supplies, leveraging its supply chain advantages and manufacturing capabilities [49][50]. Group 3: Emerging Trends - The pet vaccine sector is witnessing significant growth, with companies like Princely and Jinhe Bio reporting substantial revenue increases, indicating a burgeoning market for pet health products [78][86]. - The smart pet products market is projected to surpass 10.2 billion yuan, driven by advancements in AI and e-commerce integration [91][92]. - The "pet+" trend is gaining traction, with services like pet transportation and photography experiencing exponential growth, reflecting a shift towards emotional spending in pet ownership [106][108]. Group 4: Infrastructure and Services - Guangzhou Baiyun Airport has become the first pet-friendly airport in China, facilitating easier travel for pet owners [120][129]. - The development of pet-friendly cities and services is on the rise, enhancing the overall experience for pet owners and their pets [116][118].

Group 1 - On January 19, a total of 14 companies were investigated by institutions, with 8 companies being surveyed by funds [1] - Shu Dao Equipment received the most attention, with 4 funds participating in the survey, while Mingyang Electric and Ruipu Biotech had 3 and 2 funds respectively [1] - Among the surveyed companies, there is 1 company from the main board, 6 from the ChiNext board, and 1 from the Sci-Tech Innovation board [1] Group 2 - The total market capitalization of the surveyed A-share companies includes 1 company with a market cap over 50 billion yuan and 5 companies with a market cap below 10 billion yuan, including Tianlu Technology and Shu Dao Equipment [1] - In terms of market performance, 6 of the surveyed stocks increased in the past 5 days, with the highest gains seen in Shiji Information (21.98%), Tianlu Technology (11.08%), and Mingyang Electric (6.95%) [1] - Conversely, 2 stocks experienced declines, with Longxin Technology and Shu Dao Equipment showing the largest drops of 9.72% and 4.68% respectively [1]

Summary of the Conference Call for 瑞普生物 (Reap Bio) Company Overview - 瑞普生物 is engaged in the animal health industry, focusing on poultry products, vaccines, and pet care products. The company has shown resilience in its poultry segment and is optimizing its product structure with an increasing share of vaccine business [2][3]. Key Points Industry and Business Performance - The poultry products business remains the core driver of performance, with a significant contribution to overall revenue [2][3]. - Vaccine business has shifted from a 50:50 ratio with pharmaceuticals to a 60:40 ratio, indicating a substantial increase in vaccine sales [3]. - The pet care segment achieved record sales, nearing 1 billion yuan in 2025, marking the highest level in the company's history [3]. - The company has made breakthroughs in research and development, particularly in subunit vaccines and mRNA vaccines, with plans to launch industry-leading products [2][3]. Financial Performance and Challenges - In Q4 2025, the downturn in the pig farming sector exerted pressure on the company's continued use of formulations, but the poultry segment's profitability and emerging pet business mitigated the overall impact [2][4]. - The raw material drug business underperformed expectations, particularly with the price of florfenicol experiencing a downturn. The company plans to focus on high-margin products and optimize production capacity [2][5]. Strategic Initiatives - The company is enhancing its service model by providing comprehensive lifecycle services to major clients, which has helped maintain profitability despite market challenges [4]. - Plans to expand the customer base in the supply chain business to 20,000 pet hospitals and stores by 2028, aiming for total sales exceeding 2 billion yuan [3][8]. - The company is also pursuing international market expansion, with a goal for export revenue to account for at least 10% of total income in the next 3-5 years [11]. Product Development and Market Position - The cat trivalent vaccine is a core product in the pet segment, accounting for 30%-40% of sales, with plans for market share expansion through channel promotion and brand enhancement [6][7]. - The company is actively engaging with large-scale breeding and food processing enterprises to ensure stable growth in synthetic biology projects, particularly in the silk protein project, which has significant market potential [12]. Future Outlook - The company anticipates continued growth in the pet segment, with strong performance expected in Q4 2026, particularly during promotional events like Double Eleven [5]. - The overall strategy includes optimizing product structure and enhancing operational efficiency to sustain revenue and profit growth [3][4]. Miscellaneous - Non-operating income for Q4 is expected to be around 100 million yuan, primarily from government subsidies and investment income [10]. - The company is in the process of listing with 瑞派 (Ruipai) and has submitted necessary documentation to the Hong Kong Stock Exchange [9]. This summary encapsulates the key insights from the conference call, highlighting the company's performance, strategic initiatives, and future outlook in the animal health industry.

Group 1: Business Performance and Growth - The company's core products continue to drive growth, with the vaccine business accounting for over 50% of the overall business, becoming a key driver for product structure upgrade [2] - In 2025, the company achieved significant progress in R&D, obtaining the world's first clinical approval for an mRNA vaccine for food animals, and established a GMP mRNA vaccine production line [2] - The company has optimized internal management, resulting in a net profit growth rate significantly higher than revenue growth, showcasing operational resilience [2] Group 2: Market Expansion and Future Plans - In 2025, the company completed multiple overseas product registrations, laying the foundation for future large-scale exports [3] - Future global expansion will focus on new product registrations, acquisitions of overseas companies, and increased R&D investment to gradually enhance the export share of formulations and vaccines [3] - The company aims to deepen its market presence in the pet sector and synthetic biology, contributing to performance growth [2] Group 3: Supply Chain and Coverage - As of 2025, the company's supply chain covers approximately 7,000 pet hospitals and 4,000 pet stores, achieving a national coverage rate of about 35% [3] - Key provinces for supply chain expansion include Guangdong, Jiangsu, and Shandong, while regions like Sichuan and Fujian present untapped market opportunities [3] Group 4: Product Focus and Cost Management - The raw material drug segment will focus on high-margin products such as enrofloxacin and tobramycin, while enhancing production efficiency and reducing unit costs [3] - The company is monitoring the impact of the declining pig cycle on its livestock formulation business, maintaining profitability through comprehensive solutions for poultry clients [4] Group 5: Synthetic Biology Project - The synthetic biology project, initiated in 2025 with a total investment of 680 million yuan, aims to establish a demonstration project for the industrialization of microbial protein [3] - The project is on track, with equipment commissioning and trial production expected to commence by the end of 2026 [3]

Market Overview - The animal health sector increased by 3.21% on January 19, with Huisheng Biological leading the gains [1] - The Shanghai Composite Index closed at 4114.0, up 0.29%, while the Shenzhen Component Index closed at 14294.05, up 0.09% [1] Stock Performance - Huisheng Biological (300871) closed at 28.16, up 8.18% with a trading volume of 331,800 shares [1] - Zhongmu Co., Ltd. (600195) closed at 8.49, up 7.88% with a trading volume of 435,600 shares [1] - Other notable performers include: - Biological Co. (600201) at 18.28, up 3.80% [1] - Jinhai Biological (002688) at 6.45, up 3.53% [1] - Shunlian Biological (688098) at 9.91, up 3.23% [1] Capital Flow - The animal health sector saw a net inflow of 175 million yuan from institutional investors, while retail investors experienced a net outflow of 171 million yuan [2] - The main capital flow details include: - Huisheng Biological had a net outflow of 59.49 million yuan from institutional investors [3] - Biological Co. had a net inflow of 58.13 million yuan from institutional investors [3] - Jinhai Biological experienced a net inflow of 35.35 million yuan from institutional investors [3]

Investment Rating - The report provides an "Increase" rating for the industry, indicating a positive outlook compared to the Shanghai and Shenzhen 300 Index [46]. Core Insights - The report highlights the strengthening of pig prices, with a current price of 12.69 CNY/Kg, reflecting a week-on-week increase of 0.20 CNY/Kg. Factors contributing to this trend include a decrease in sales plans for January and the anticipated impact of a nationwide cold wave starting January 19, which may further boost prices [5][10]. - In the planting sector, corn and soybean prices have shown stability, with corn prices at 2364 CNY/ton (up 0.5% week-on-week) and soybean prices at 4072 CNY/ton (up 0.6% week-on-week). The report expresses optimism for the recovery of planting sector profitability [3][10]. - The pet industry is experiencing increased attention due to major exhibitions, with significant events scheduled in March 2026, which are expected to catalyze new product launches from leading domestic brands [4]. Summary by Sections Livestock - The report notes that pig prices are on the rise, with a current price of 12.69 CNY/Kg, up 1.60% week-on-week and 10.06% month-on-month, although down 19.33% year-on-year. The report suggests that the cold wave and increased demand during the lunar month will be key factors influencing future price movements [5][10]. - Recommended stocks in the livestock sector include Muyuan Foods, Wens Foodstuffs, and others, with a focus on companies that are expected to benefit from the recovery in pig prices [5][40]. Planting - The report indicates that corn and soybean prices are stable, with corn at 2364 CNY/ton and soybeans at 4072 CNY/ton. The planting sector is expected to see a recovery in profitability, particularly benefiting seed companies that focus on high-quality products [3][10]. Pet Industry - Major pet exhibitions are set to take place in March 2026, which are expected to enhance market interest and lead to new product launches from top brands. The report emphasizes the potential for growth in the pet sector due to these events [4][10]. Key Company Coverage - The report includes earnings forecasts and valuations for key companies in the industry, with all covered companies receiving an "Increase" rating. Notable companies include Muyuan Foods, Wens Foodstuffs, and various firms in the pet and agricultural sectors [40].